SEK 2.76
(-8.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | -5.00 SEK | -100.0% |
2022 | 375 Thousand SEK | -94.72% |
2021 | 7.1 Million SEK | 81.29% |
2020 | 3.91 Million SEK | -16.71% |
2019 | 4.7 Million SEK | 36.03% |
2018 | 3.45 Million SEK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 Q4 | 3.00 SEK | -100.0% |
2023 Q3 | 1.13 Million SEK | 202.11% |
2023 Q1 | 1.28 Million SEK | -32.23% |
2023 FY | -5.00 SEK | -100.0% |
2023 Q2 | -1.11 Million SEK | -187.08% |
2022 FY | 375 Thousand SEK | -94.72% |
2022 Q4 | 1.89 Million SEK | 96.93% |
2022 Q3 | 960.4 Thousand SEK | 0.0% |
2022 Q2 | - SEK | 100.0% |
2022 Q1 | -2.00 SEK | 60.0% |
2021 Q1 | 1.15 Million SEK | 0.0% |
2021 FY | 7.1 Million SEK | 81.29% |
2021 Q4 | -5.00 SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2020 FY | 3.91 Million SEK | -16.71% |
2019 FY | 4.7 Million SEK | 36.03% |
2018 FY | 3.45 Million SEK | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
AcuCort AB | 13.24 Million SEK | 100.0% |
AlzeCure Pharma AB (publ) | 38.26 Million SEK | 100.0% |
BioGaia AB (publ) | 507.08 Million SEK | 100.0% |
Enzymatica AB (publ) | 79.92 Million SEK | 100.0% |
Enorama Pharma AB (publ) | 38.22 Million SEK | 100.0% |
Gabather AB (publ) | 9.47 Million SEK | 100.0% |
Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | 100.0% |
Moberg Pharma AB (publ) | 27.46 Million SEK | 100.0% |
Nanexa AB (publ) | 135.78 Million SEK | 100.0% |
Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | 100.0% |
Orexo AB (publ) | 659.4 Million SEK | 100.0% |
Probi AB (publ) | 208.93 Million SEK | 100.0% |
Swedencare AB (publ) | 1.12 Billion SEK | 100.0% |
Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 100.0% |
Toleranzia AB | 6.97 Million SEK | 100.0% |
Vivesto AB | 355.71 Million SEK | 100.0% |